Slebos, Dirk-Jan
,
Degano, Bruno
Valipour, Arschang
Shah, Pallav L.
Deslée, Gaetan
Sciurba, Frank C.
Funding for this research was provided by:
Nuvaira (Sponsor)
Article History
Received: 18 September 2019
Accepted: 23 January 2020
First Online: 13 February 2020
Ethics approval and consent to participate
: The study (Protocol D0543, dated 31 May 2019) is designed in accordance with the Declaration of Helsinki and approved by the Ethics Committee of the City of Vienna (Austria), Comité de Protection des Personnes (CPP) OUEST II – Angers (France), Ethics Committee of the Faculty of Heidelberg (Germany), University Medical Center Groningen (UMCG) Medical Ethics Review Board (Netherlands), East of England – Cambridge East Research Ethics Committee (United Kingdom), Western Institutional Review Board (WIRB; United States) and John Hopkins Medical Institutional Review Board (United States). Written informed consent will be obtained from all participants.
: The ethical approval and patient information include consent to publish collected data.
: BD reports grants and personal fees from Novartis, Actelion and consultation fees from Nuvaira, PneumRx, Teva, GSK, AstraZeneca, Chiesi, Menarini and Boehringer Ingelheim France. GD has received consultation fees from Nuvaira. All clinical trial activities are sponsored by Nuvaira, Inc.